All articles tagged: News Alert
MedScape
02 July at 03.54 PM
FDA Approves Donanemab for Early Alzheimer'sThe FDA has approved the anti-amyloid donanemab for early symptomatic Alzheimer's, which includes MCI or mild dementia stage of disease, with confirmed amyloid pathology. |
MedScape
01 July at 03.59 PM
FDA Approves Third Ustekinumab BiosimilarThe biosimilar is approved for all indications of the reference medication, Stelara, and will launch in February 2025. |
MedScape
28 June at 01.34 PM
Europe Endorses Its First mRNA Vaccine for RSVModerna's mRNA vaccine mRESVIA has been recommended for a marketing authorization in the EU to protect against respiratory syncytial virus in older adults. |
MedScape
28 June at 12.55 PM
EMA Greenlights Four Drugs for Bladder and Other CancersThe positive opinions pave the way for new treatment options in Europe for urothelial carcinoma, prostate cancer, lymphoma, and leukemia. |
MedScape
28 June at 11.14 AM
New Drugs Turned Down by EU Safety AssessorDrugs for ALS, age-related macular degeneration, and Duchenne muscular dystrophy did not get the green light due to lack of evidence. |
MedScape
28 June at 10.40 AM
Pulmonary Arterial Hypertension Drug OK'd by EuropeWinrevair improves exercise capacity in patients with the condition while taking background therapy. |
MedScape
28 June at 10.00 AM
First Nasal Adrenaline Spray for Anaphylaxis Backed by EMAA nasal spray could help overcome obstacles to using autoinjectors for rapid treatment of anaphylaxis, the European Medicines Agency said. |
MedScape
27 June at 08.34 AM
FDA Approves Epcoritamab for R/R Follicular LymphomaThe new approval follows the BiTE's first approval in 2023 for DLBCL. |
MedScape
27 June at 06.00 AM
Europe Approves Fruzaqla for Metastatic Colorectal CancerThe European Commission has authorized the use of Fruzaqla as a monotherapy for previously treated adult patients with metastatic colorectal cancer. |
MedScape
25 June at 08.25 AM
FDA Approves New Treatment for Excessive Underarm SweatingApproval of the topical anticholinergic was based on two phase 3 trials that enrolled 710 patients. |
MedScape
21 June at 05.05 PM
FDA Approves Adagrasib for KRAS G12C–Mutated CRCThis marks the first approval for a KRAS inhibitor to treat CRC. |
MedScape
21 June at 11.27 AM
Europe OKs Marketing of Hemophilia A DrugAltuvoct is used to treat and prevent bleeds and for perioperative prophylaxis in people of all ages with hemophilia A. |
MedScape
21 June at 10.45 AM
Truqap Combo Earns EU Approval for Advanced Breast CancerThe approval is based on positive results from the phase 3 CAPItello-291 trial. |
MedScape
19 June at 12.38 PM
FDA Approves Skyrizi for Ulcerative ColitisThe approval is the fourth indication for the anti–interleukin 23 monoclonal antibody after approval for Crohn's disease, psoriatic arthritis, and plaque psoriasis. |
MedScape
18 June at 01.49 PM
New Pneumococcal Vaccine ApprovedThe new vaccine covers eight serotypes not protected by other vaccines already on the market. |
MedScape
17 June at 06.24 AM
FDA Expands Durvalumab Label to Endometrial CancerThe approval for mismatch repair deficient newly diagnosed advanced or recurrent endometrial cancer was based on improved progression-free survival vs placebo across 95 women. |
MedScape
13 June at 05.17 PM
FDA Expands Repotrectinib LabelThe new accelerated approval for the TKI was based on the overall response rate in 48 patients. |
MedScape
11 June at 03.07 PM
FDA OKs Sarilumab for Polyarticular JIAThe approval applies to patients weighing ≥ 63 kg, the announcement said. |
MedScape
11 June at 12.13 PM
FDA OKs Iqirvo, First-in-Class PPAR Treatment for PBCIqirvo (elafibranor) is indicated for adults with primary biliary cholangitis who do not respond to or cannot tolerate ursodeoxycholic acid. |
MedScape
11 June at 05.12 AM
FDA Approves Expansion of Treatment Area for AK TreatmentApproval was based on a phase 3, open-label study of adults with AKs. |
MedScape
07 June at 03.02 PM
FDA Approves Imetelstat for Rare Low-Risk Blood CancerThe approval for the first-in-class agent is "potentially practice changing" given the lack of treatment options for transfusion-dependent lower-risk MDS patients. |
MedScape
04 June at 05.12 PM
FDA Extends Upadacitinib Indications to Kids With ArthritisThe JAK inhibitor's safety profile for patients as young as 2 years was similar to known to the known safety profile in adults. |
MedScape
03 June at 07.02 PM
Moderna's RSV Vaccine Approved by FDAFor the first time, an mRNA vaccine has been approved for an indication other than COVID-19. The vaccine will join a couple other immunizations currently on the market for respiratory syncytial virus. |
MedScape
31 May at 03.13 PM
Severe Hypoglycemia in Diabetes Drug Approved in EuropeTreatment of insulin-induced hypoglycemia with Zegalogue reduced recovery time from severe hypoglycemia, the European Medicines Agency said. |
MedScape
31 May at 02.31 PM
EMA Panel Nods to Seven New Cancer DrugsThe drugs include an anti–PD-L1 monoclonal antibody, a biosimilar, and five generics, with indications covering a wide spectrum of cancers. |
MedScape
31 May at 01.08 PM
Europe Drops UK 'Mad Cow' Blood BanPreviously, the EU protected against Creutzfeldt-Jakob disease transmission by banning blood donations from those who lived in the UK during its 1980s "mad cow" era. |
MedScape
31 May at 12.10 PM
EMA Authorizes Hemophilia B Gene TherapyThe European Medicines Agency has given the go-ahead for Durveqtix to treat hemophilia B in adults and to Adzynma for patients with congenital thrombotic thrombocytopenic purpura. |
MedScape
31 May at 10.15 AM
Chikungunya Vaccine Backed by European Medicines AgencyIxchiq is the first vaccine for protection against chikungunya to be recommended for European Union countries. |
MedScape
30 May at 08.46 AM
FDA Approves Nonstimulant Liquid Onyda XR for ADHDThe centrally acting alpha2-adrenergic agonist allows for nighttime dosing and can be used with stimulants, the drug's manufacturer says. |
MedScape
21 May at 04.16 PM
FDA Approves Belimumab Autoinjector for Pediatric LupusThis enables at-home administration of the medication, which was previously available only via intravenous infusion. |
MedScape
21 May at 06.33 AM
FDA Grants Withdrawal of Infigratinib for CholangiocarcinomaThe drug company voluntarily requested the withdrawal of infigratinib, citing challenges enrolling patients for the required confirmatory postmarketing trials. |
MedScape
16 May at 06.20 PM
FDA Approves Tarlatamab for Extensive-Stage SCLCContinued approval of the first-in-class bispecific T-cell engager (BiTE) may depend on proof of clinical benefit. |
MedScape
16 May at 07.05 AM
FDA Broadens Breyanzi's Follicular Lymphoma IndicationThe overall response rate to the CAR T therapy was 95.7% in phase 2 testing. |
MedScape
08 May at 03.19 PM
Tandem Recall Urges Updating App Used With Insulin PumpThe recall warns of a software glitch with the t:connect mobile app that can lead to battery failure of the t:slim X2 insulin pump. |
MedScape
07 May at 04.18 PM
FDA OKs First Multitarget Stool RNA Test for CRC ScreeningRelative to fecal immunochemical testing, the multitarget stool RNA test ColoSense showed a significant improvement in sensitivity for colorectal cancer and advanced adenomas. |
MedScape
02 May at 12.34 PM
FDA OKs High-Concentration of Adalimumab Biosimilar CyltezoUnlike the low-concentration formulation of adalimumab-adbm, launched July 1, 2023, this high-concentration version has not yet been granted an interchangeability designation. |
MedScape
26 April at 02.52 PM
FDA Approves New Antibiotic for Uncomplicated UTIsThe US Food and Drug Administration has approved pivmecillinam (Pivya) tablets to treat uncomplicated urinary tract infections in women. |
MedScape
26 April at 02.04 PM
EMA Approves Factor VIII Deficiency Clotting DrugEuropean Union marketing authorization recommended for Altuvoct for hemophilia A caused by factor VIII deficiency. |
MedScape
26 April at 01.09 PM
Drug for Overactive Bladder Recommended in EuropeObgemsa is suitable for treating symptoms of an overactive bladder in adults, the European Medicines Agency has determined. |
MedScape
26 April at 12.41 PM
New Contraindications to Coadministration of AtazanavirNew restrictions have been imposed by the European Medicines Agency on the coadministration of the anti-HIV drug atazanavir with a variety of other agents. |
MedScape
26 April at 11.51 AM
Two Biosimilars Approved in Europe for Autoimmune DisordersThe drugs are intended to treat several types of arthritis, psoriasis, COVID-19, and Crohn's disease. |
MedScape
26 April at 11.12 AM
Europe Recommends Three Cancer DrugsThe European Medicines Agency has recommended Fruzaqla, Truqap, and Eribulin Baxter for use in the treatment of specific colorectal and breast cancers. |
MedScape
26 April at 10.00 AM
FDA Approves Second Gene Therapy for Hemophilia BPfizer reported a list price of $3.5 million for its new gene therapy, Beqvez, for adults with this rare bleeding disorder. |
MedScape
23 April at 11.01 AM
Europe Approves Paroxysmal Nocturnal Hemoglobinuria DrugThe factor D inhibitor danicopan has been approved for use in Europe for patients with paroxysmal nocturnal hemoglobinuria with residual hemolytic anemia on standard therapy. |
MedScape
23 April at 09.02 AM
FDA Approves New Bladder Cancer DrugThe first-in-class agent is approved alongside bacillus Calmette-Guérin to treat certain non–muscle-invasive bladder cancers that do not respond to bacillus Calmette-Guérin alone. |
MedScape
22 April at 04.45 AM
Alectinib Approved for ALK-Positive Adjuvant NSCLCThe approval makes alectinib the first ALK inhibitor approved for early-stage NSCLC. |
MedScape
19 April at 03.15 PM
FDA OKs Sub-Q Vedolizumab for Crohn's Maintenance TherapySubcutaneous administration of vedolizumab is now approved for maintenance therapy in adults with moderate to severe active Crohn's disease after induction therapy with intravenous vedolizumab. |
MedScape
17 April at 05.17 PM
FDA Approves Second Ustekinumab BiosimilarThe biosimilar is expected to be marketed in the United States on or after February 21, 2025. |
MedScape
16 April at 02.08 PM
CDC Investigating Reactions Linked to Counterfeit 'Botox'Reactions have included blurry vision, double vision, drooping eyelids, difficult swallowing or breathing, and other symptoms of botulism. |
MedScape
15 April at 06.00 AM
FDA Approves AI Diagnostic Tool for Early Sepsis DetectionThe first-ever AI diagnostic tool for sepsis was granted marketing authorization through the FDA's De Novo pathway. |
MedScape
11 April at 02.21 PM
FDA Expands Benralizumab Use for Asthma to Kids Over Age 6The maintenance treatment for severe asthma with an eosinophilic phenotype originally was approved for patients aged 12 years and older. |
MedScape
08 December at 03.35 PM
FDA Clears Becton's Less-Invasive Blood Collection DeviceBecton Dickinson said on Thursday the FDA cleared its finger-prick blood collection device that could provide a less-invasive option for some commonly ordered lab tests. |
MedScape
30 November at 09.22 AM
FDA Clears Vivos Therapeutics' Oral Device for Sleep ApneaVivos Therapeutics said on Wednesday the US health regulator has cleared its oral device for severe obstructive sleep apnea, leading a massive rally in the company's shares before the bell. |
MedScape
28 November at 04.47 PM
FDA Investigates Secondary Cancers From CAR T-Cell TherapiesThe FDA has determined that the risk for lymphoma and other T-cell cancers may apply to approved BCMA- and CD-19–directed CAR T-cell immunotherapies. |
MedScape
28 November at 04.16 PM
FDA Warns of Potentially Lethal Reaction to Seizure MedsLevetiracetam and clobazam can cause a rare but serious drug reaction with eosinophilia and systemic symptoms that can be life threatening if not diagnosed and treated quickly, the FDA warns. |
MedScape
28 November at 02.41 PM
FDA OKs New Agent to Block Chemotherapy-Induced NeutropeniaThe new colony-stimulating factor from China proved comparable to pegfilgrastim (Neulasta) in clinical testing. |
MedScape
28 November at 02.41 PM
FDA OKs New Agent to Block Chemotherapy-Induced NeutropeniaThe new colony-stimulating factor from China proved comparable to pegfilgrastim (Neulasta) in clinical testing. |
MedScape
27 November at 06.14 PM
FDA Approves Nirogacestat for Desmoid TumorsThis is the first drug approved to treat desmoid tumors. |
MedScape
20 November at 02.14 PM
FDA OKs Symplicity Renal Denervation System for HypertensionAfter a mixed FDA panel review in August, the agency has approved Medtronic's Symplicity Spyral renal denervation system for treatment of hypertension. |
MedScape
17 November at 03.26 PM
FDA Expands Enzalutamide Approval to Earlier Prostate CancerThe expanded approval makes enzalutamide the first and only approved androgen receptor signaling inhibitor in the nonmetastatic castration-sensitive prostate cancer setting. |
MedScape
17 November at 10.52 AM
FDA OKs First-Line Pembro With Chemo for Gastric/GEJ CancerAdding pembrolizumab to chemotherapy had significant benefits in patients with locally advanced unresectable or metastatic, HER2-negative gastric or gastroesophageal junction adenocarcinoma. |
MedScape
17 November at 09.11 AM
FDA OKs Capivasertib for Certain Advanced Breast CancersThe first-in-class AKT inhibitor administered with fulvestrant prolonged PFS vs fulvestrant alone in patients with PIK3CA/AKT1/PTEN-altered tumors. |
MedScape
16 November at 02.45 PM
FDA Approves Repotrectinib for ROS1-Positive NSCLCThe next-generation tyrosine kinase inhibitor provides a new treatment option for patients with this difficult-to-treat form of lung cancer. |
MedScape
10 November at 09.03 AM
FDA Approves First Drug for Rare, Deadly Clotting DisorderAdzynma is the first treatment to become available for patients with congenital thrombotic thrombocytopenic purpura. |
MedScape
09 November at 02.09 PM
FDA Approves Fruquintinib for Metastatic Colorectal CancerThis marks the first approval for the oral anti-VEGFR tyrosine kinase inhibitor. |
MedScape
08 November at 02.59 PM
FDA Approves Tirzepatide for Treating ObesityTirzepatide, the active ingredient in Eli Lilly’s Zepbound, is already approved under the name Mounjaro for the treatment of type 2 diabetes. |
MedScape
07 November at 07.31 AM
FDA Warns About Over-the-Counter Glucose-Lowering ProductNow-discontinued "Dr. Ergin's SugarMD Advanced Glucose Support" was found to contain glyburide and metformin, which are only available by prescription. |
MedScape
02 November at 03.42 PM
FDA OKs New Treatment for Erosive EsophagitisVonoprazan (Voquezna) is indicated for the healing and maintenance of healing of all grades of erosive esophagitis, as well as relief of associated heartburn in adults. |
MedScape
01 November at 05.15 PM
Pembrolizumab Wins Biliary Tract Cancer IndicationThe new approval is the sixth gastrointestinal indication for the checkpoint inhibitor. |
MedScape
01 November at 12.15 PM
FDA Approves First Ustekinumab BiosimilarThe drug has also been granted an interchangeability designation and has been approved for six indications. |
MedScape
31 October at 08.27 PM
FDA Approves Secukinumab for Adults With HSThis marks the second FDA-approved agent for the condition, and the first IL-17A inhibitor. |
MedScape
30 October at 05.09 PM
FDA Approves Toripalimab for Nasopharyngeal CarcinomaThis marks the first approval for toripalimab. |
MedScape
30 October at 01.05 PM
FDA Clears First OTC Fentanyl Urine TestThe Alltest fentanyl urine test provides a preliminary result; a more specific alternative chemical method, confirmation testing, is required to confirm the result. |
MedScape
27 October at 01.34 PM
FDA Approves New Drug for Ulcerative ColitisMirikizumab (Omvoh) is the first IL-23 inhibitor to be approved in the United States for the treament of moderately to severely active ulcerative colitis. |
MedScape
27 October at 01.34 PM
FDA Approves Mirikizumab for Ulcerative ColitisMirikizumab (Omvoh) is the first IL-23 inhibitor to be approved in the United States for the treament of moderately to severely active ulcerative colitis. |
MedScape
27 October at 01.05 PM
FDA Okays Drug for Duchenne Muscular DystrophyVamorolone (Agamree) is a structurally unique steroidal anti-inflammatory drug with fewer side effects than traditional corticosteroids. |
MedScape
25 October at 04.44 PM
FDA Warns of Hidden Ingredients in Arthritis, Pain ProductsCertain products may contain active ingredients found in prescription-only drugs. |
MedScape
25 October at 12.11 PM
FDA Approves Triple Combination Topical Treatment for AcneThe product combines an antibiotic, a retinoid, and an antibacterial in a gel formulation. |
MedScape
25 October at 10.18 AM
FDA OKs Ivosidenib for IDH1-mutated Myelodysplastic SyndromesThe FDA approval was based on a small study, in which 38.9% of patients with relapsed or refractory disease went into complete remission. |
MedScape
24 October at 02.11 PM
FDA Okays First Extravascular ICD SystemMedtronic's Aurora extravascular implantable cardioverter-defibrillator system uses a single lead implanted substernally to allow anti-tachycardia pacing and low-energy defibrillation. |
MedScape
23 October at 05.51 PM
FDA Approves Subcutaneous Infliximab for IBDThe approval provides an alternative administration option for delivering the drug to patients with moderately to severely active ulcerative colitis or Crohn's disease. |
MedScape
23 October at 02.52 PM
New Meningococcal Vaccine Wins FDA ApprovalThe single shot will cover the five most common serogroups that cause meningococcal disease in children and young adults. |
MedScape
23 October at 09.58 AM
BioMarin's Dwarfism Therapy Gets FDA Nod for Expanded UseThe US health regulator has approved the expanded use of BioMarin Pharmaceutical's once-daily injection to treat children under the age of 5 with the most common form of short-limbed dwarfism. |
MedScape
18 October at 01.44 PM
FDA Approves Bimekizumab for Plaque Psoriasis in AdultsBimekizumab is the first IL-17A and IL-17F inhibitor approved by the FDA for adults with psoriasis. |
MedScape
18 October at 09.14 AM
FDA Approves New Drug for Generalized Myasthenia GravisZilucoplan is the first once-daily, subcutaneous, self-administered, targeted C5 complement inhibitor for adults with gMG who are AChR antibody positive. |
MedScape
17 October at 05.16 PM
FDA OKs Neoadjuvant/Adjuvant Pembrolizumab in NSCLCThe approval allows for continuous immunotherapy treatment around surgery for resectable non-small cell lung cancer. |
MedScape
16 October at 02.24 PM
FDA Approves Nivolumab for Resected Stage IIB/C MelanomaThe new approval expands the melanoma indication for nivolumab to earlier-stage disease. |
MedScape
13 October at 01.10 PM
FDA Approves New Drug for Ulcerative ColitisEtrasimod is the second oral sphingosine-1-phosphate (S1P) receptor approved in the US for treating moderate to severe active ulcerative colitis in adults. |
MedScape
12 October at 04.56 PM
FDA OKs Drug Combo in BRAF V600E-Mutated Metastatic NSCLCThe single-arm approval study reported an objective response rate of 75% among treatment-naive patients. |
MedScape
10 October at 02.22 PM
FDA Denies Approval for Patisiran in ATTR CardiomyopathyIn a complete response letter, the FDA said the clinical meaningfulness of patisiran's effects in cardiomyopathy of ATTR amyloidosis are not established, despite good reviews from an advisory panel. |
MedScape
09 October at 06.40 PM
FDA Approves Intravenous Formulation of SecukinumabThis new route of administration is expected to become available during the fourth quarter of 2023. |
MedScape
05 October at 05.30 PM
FDA OKs Ninth Humira Biosimilar, With InterchangeabilityThe drug, adalimumab-afzb (Abrilada), is the second adalimumab biosimilar approved with interchangeability status. It will be available later this month. |
MedScape
04 October at 09.21 AM
FDA Authorizes Novavax's Updated COVID ShotThe FDA said on Tuesday it authorized an updated version of Novavax's COVID-19 vaccine for emergency use in individuals aged 12 years and older. |
MedScape
29 September at 05.58 PM
FDA Approves First Tocilizumab BiosimilarTocilizumab-bavi (Tofidence) will offer a lower-cost option for patients with autoimmune conditions, the drug manufacturer, Biogen, stated. |
MedScape
28 September at 12.42 PM
FDA OKs Subcutaneous Vedolizumab for UC Maintenance TherapyTakeda expects subcutaneous vedolizumab for UC maintenance therapy to be available in the United States as a single-dose pre-filled pen (Entyvio Pen) by the end of October. |
MedScape
27 September at 03.54 PM
FDA Approves Bosutinib for Children With CMLThe agency approved the tyrosine kinase inhibitor for pediatric patients with chronic phase Ph+ chronic myelogenous leukemia that is newly diagnosed or resistant or intolerant to prior therapy. |
MedScape
27 September at 03.32 PM
Empagliflozin Gets FDA Nod for CKD Without T2D or HFThe US Food and Drug Administration gave the SGLT2 inhibitor empagliflozin (Jardiance) a new indication for treating adults with isolated chronic kidney disease. |
MedScape
19 September at 04.46 PM
European Commission Approves Ritlecitinib for Severe AAThis makes ritlecitinib the first medicine authorized by the EC to treat individuals with severe alopecia areata as young as 12 years of age. |
MedScape
15 September at 07.08 PM
FDA Approves Momelotinib for Myelofibrosis With Anemia"Momelotinib is an important emerging agent for these more anemic patients," one expert said. |
MedScape
14 September at 05.23 PM
FDA Updates Indications for TemozolomideThis is the second drug to receive a labeling update under the agency's Project Renewal program, which aims to keep labels of older cancer drugs up to date with current practice. |
MedScape
14 September at 04.04 PM
FDA OKs LimFlow for Serious PAD, Reroutes Blood Via VeinsThe transcatheter stent-like device diverts arterial flow to the lower-extremity venous system to treat 'no-option' patients with chronic limb-threatening ischemia. |
MedScape
11 September at 04.00 PM
FDA OKs Motixafortide for Stem Cell Mobilization in MyelomaThe GENESIS trial reported substantially better stem cell mobilization when patients with multiple myeloma received motixafortide alongside filgrastim. |
MedScape
11 September at 03.12 PM
FDA Authorizes New COVID-19 VaccineThe FDA today authorized the newest COVID-19 vaccine, the first not to target the initial or 'ancestral' strain of the virus. |
MedScape
06 September at 09.10 AM
UK Regulator Approves Updated Pfizer-BioNTech COVID VaccineThe UK drug regulator said on Tuesday it has approved an updated COVID-19 vaccine by Pfizer and its German partner BioNTech that targets only the Omicron XBB.1.5 subvariant. |
MedScape
05 September at 03.23 PM
PRAC Recommends New Restrictions on Topiramate in PregnancyThe EMA safety committee recommends new measures to limit topiramate use in young women based on recent data suggesting more neurodevelopmental disorders for offspring when it's used during pregnancy. |
MedScape
30 August at 08.54 AM
FDA Clears New Capabilities for Diabetes App BlueStarThe app-based system can now make insulin dose recommendations based on continuous glucose monitor (CGM) data. |
![]()
Medical xPress
30 June at 07.40 AM
Decision to offer sedation for often-painful IUD insertion is 'groundbreaking,' health experts sayIntrauterine devices (IUDs) are a highly effective and long-lasting form of birth control placed in the uterus. Research shows that many people who get IUDs experience moderate to intense pain during the insertion. But it wasn't until recently that providers began to acknowledge this and do something about it. |
![]()
HealthDay
27 June at 03.19 PM
Immunoglobulin Replacement Therapy Beneficial for Blood CancersImmunoglobulin replacement therapy (IgRT) is associated with reductions in hypogammaglobulinemia, infections, severe infections, and associated antimicrobial use among real-world patients with chronic lymphocytic leukemia (CLL) or non-Hodgkin lymphoma (NHL), according to a study published online June 21 in Blood Advances.Jacob D. Soum |
Medpage Today
26 June at 04.59 PM
When Was the Last Time You Really Talked With Your Patient?My 10 o'clock patient's name is Maria*. Her chart has three "health maintenance" flags that are bright red, indicating that she is more than 3 years overdue for a mammogram, more than 6 years overdue for a Pap smear, and has... |
Medpage Today
23 June at 09.21 PM
Novel Triple-Hormone Agonist Boosts Beta-Cell Function in T2DORLANDO -- An investigational triple-hormone receptor agonist improved metabolic profiles of people with obesity with or without type 2 diabetes, an exploratory biomarker analysis of a phase II trial found. After 36 weeks... |
Medpage Today
22 June at 06.00 PM
Fenofibrate Slows Diabetic Retinopathy ProgressionORLANDO -- The cholesterol drug fenofibrate reduced progression of early eye disease among diabetes patients, the LENS trial showed. The fibrate reduced progression of early diabetic retinopathy or maculopathy by a relative... |
Medpage Today
22 June at 06.00 PM
Preventing Surgical-Site Infections; Drugs Go Head to Head for Ischemic StrokeTTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine in Baltimore, and Rick Lange, MD, president of the Texas Tech University Health Sciences Center... |
![]()
Medical xPress
22 June at 05.20 PM
Lawsuit could challenge trust in Ozempic and other popular weight loss drugsThe manufacturers of the most popular weight loss drugs are being challenged in court. |
![]()
HealthDay
21 June at 03.38 PM
Overall Prevalence of Being Up-to-Date With Lung Cancer Screening Is LowThe overall prevalence of up-to-date (UTD) lung cancer screening (LCS) was low in 2022, with prevalence increasing with age and number of comorbidities, according to a study published online June 10 in JAMA Internal Medicine.Priti Bandi, Ph.D., from the American Cancer Society in Atlanta, and colleagues estimated the contemporary preval |
Medpage Today
13 June at 06.56 PM
Upping Immunotherapy Activity; A Win for Lung Screening; Looming Drug Price Break?Finding a way to dissociate the activity of effector T cells from regulatory T cells could make immune checkpoint inhibitors more effective in the 60% of melanoma patients who do not benefit or develop resistance to the drugs... |
Medpage Today
08 June at 04.00 PM
Here Are the Top Supreme Court Health Cases to WatchBy early July, the Supreme Court will release its most controversial rulings for the 2023-2024 term. The Court's 6-3 conservative supermajority has already overturned Roe v. Wade, sharply limited affirmative action, expanded... |